速递｜一针一周的组合拳：IcoSema在华获批，诺和诺德把胰岛素和GLP-1装进同一支笔

Core Viewpoint - The approval of IcoSema, a combination of long-acting insulin and GLP-1 receptor agonist, addresses the dual challenges of managing HbA1c levels while minimizing weight gain and treatment complexity in type 2 diabetes management in China [5][8][10] Summary by Sections Product Overview - IcoSema combines two active ingredients: icodec, a long-acting insulin with a half-life of approximately 200 hours, and semaglutide, a GLP-1 receptor agonist with a half-life of about 165 hours, allowing for weekly injections [5] - This combination aims to simplify treatment pathways for patients transitioning from oral medications to insulin therapy, addressing concerns about injection complexity and weight gain [8] Clinical Evidence - The efficacy of IcoSema is supported by three Phase III studies (COMBINE 1, 2, and 3), demonstrating superior HbA1c reduction compared to traditional insulin and semaglutide alone [9] - COMBINE 1 showed a greater reduction in HbA1c with IcoSema while highlighting a divergence in weight changes, indicating metabolic benefits of the combination [9] - COMBINE 2 indicated that while IcoSema is effective for HbA1c improvement, its weight management effects are less pronounced than those of semaglutide alone, suggesting it is tailored for patients needing stronger glycemic control [9] - COMBINE 3 reinforced IcoSema's advantages in complex insulin regimens, showing effective glycemic control with reduced weight burden [9] Market Implications - The approval of IcoSema represents a strategic positioning for Novo Nordisk in the competitive GLP-1 market in China, shifting focus from single-agent GLP-1 competition to comprehensive glycemic control solutions [10] - The market penetration of IcoSema will depend on pricing, acceptance among healthcare providers, and its positioning relative to existing treatments like semaglutide and long-acting insulin [10] - IcoSema is expected to first be adopted in specialized endocrinology and chronic disease management settings before expanding to broader outpatient follow-up scenarios [10]